SANTA CLARA, Calif., June 6 /PRNewswire-FirstCall/ -- XenoPort, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a public offering of 4,500,000 shares of its common stock. All of the shares will be offered by XenoPort.
XenoPort expects to grant the underwriters in the offering an over- allotment option for 675,000 shares of common stock. Morgan Stanley & Co. Incorporated is acting as the sole book running and lead manager for the offering. Deutsche Bank Securities Inc. and Pacific Growth Equities, LLC are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, preliminary prospectuses may be obtained from Morgan Stanley's prospectus department at 180 Varick, New York, NY, 10014, by telephone at 866-718-1649 or by emailing
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort's most advanced product candidate, XP13512, has commenced a Phase 3 clinical program for the treatment of Restless Legs Syndrome, and has successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia. XenoPort has also completed two Phase 1 clinical trials of its second product candidate, XP19986, and reported preliminary positive results of a Phase 2a clinical trial of XP19986 in Gastroesphageal Reflux Disease, or GERD, patients.
NOTE: XenoPort and Transported Prodrug are U.S. trademarks of XenoPort, Inc.
XNPT2F
© 2006 PR Newswire
